Statement re Director Options

Advanced Medical Solutions Grp PLC
13 July 2004


For Immediate Release                                07:00, Tuesday 13 July 2004

                        Advanced Medical Solutions Group
              Announce lapse and issue of Executive Share Options


Winsford, UK: Advanced Medical Solutions, (AIM: AMS), the global wound care
technology company, today announced that as a result of issuing new share
options to all employees to replace options which have lapsed as a result of the
Company's Share Option Scheme performance conditions, Chief Executive Officer,
Don Evans no longer has interest in 1,850,000 lapsed share options which
represented 71.2% of his total holding in share options. These share options
have been replaced by 616,666 new share options. As a consequence, Don Evans now
has an interest in 1,366,666 options representing 0.96% of the Company's issued
share capital. The Finance Director, Mary Tavener no longer has interest in
900,000 lapsed share options which represented 70.6% of her total holding in
share options. These have been replaced by 300,000 new share options. Mary
Tavener now has an interest in 675,000 options representing 0.48% of the issued
share capital. These new options will be priced at the average market price over
the next three business days and are subject to performance conditions over a
three year period to vest.


                                    - ENDS -


For further information, please contact:

Advanced Medical Solutions Group plc                   Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                                Tel: [phone]
Mark Court, Mary-Jane Johnson


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith + Nephew and Beiersdorf.



                      This information is provided by RNS
            The company news service from the London Stock Exchange